Core Viewpoint - The company has shown strong growth in new orders for its energy source equipment, particularly in the Asia-Pacific region, leading to double-digit year-on-year revenue growth in the third quarter of 2025 [1][2]. Group 1: Energy Source Equipment - The demand for energy source equipment in the Asia-Pacific market is robust, with new orders in Q3 showing double-digit growth [1]. - The company's energy source equipment revenue faced challenges in the first half of the year due to high interest rates and weak consumer demand in North America, but there has been a noticeable recovery in Q3 [2]. - The flagship energy source device, Alma Harmony, has received a strong market response since its global launch in March 2025, contributing to increased order volumes [2]. Group 2: Injection Fillers - The injection filler business experienced a significant growth of 218% in the first half of the year, demonstrating strong product capability and effective channel management [3]. - The company plans to enhance the promotion of Profhilo in Thailand and expand the sales of Revanesse in the UK, German-speaking regions, Australia, and New Zealand [3]. - The long-acting botulinum toxin product, DaxibotulinumtoxinA (达希斐), is set to be launched in China following approval in September 2024, which is expected to inject new growth momentum into the injection filler business [3][4]. Group 3: Market Potential - The penetration rate of botulinum toxin in China is currently below the global average, indicating significant growth potential as consumer awareness increases [3]. - The market structure differences between China and other countries highlight the potential for increased usage of botulinum toxin in the Chinese market, which is currently underdeveloped compared to hyaluronic acid [3]. - The company’s DaxibotulinumtoxinA product has shown rapid revenue growth since its approval in the U.S., with a 32% increase in revenue for the first three quarters of 2024, primarily driven by repeat purchases [4]. Group 4: Financial Projections - The company expects revenue to reach $382 million, $442 million, and $510 million for the years 2025, 2026, and 2027, respectively, with net profits projected at $29 million, $36 million, and $45 million [4]. - The earnings per share (EPS) are forecasted to be $0.06, $0.08, and $0.10 for the same years, indicating a favorable growth trajectory [4].

Core Viewpoint - Foryou Medical Technology (01696) reported strong growth in new orders for Q3 2025, driven by performance in China, South Korea, and Thailand markets [1] Group 1: Financial Performance - The company achieved a double-digit year-on-year growth in unaudited revenue for the quarter [1] Group 2: Product Development and Market Expansion - The flagship multi-functional device, Alma Harmony, experienced steady growth during the quarter [1] - The company plans to enhance the penetration of the Soprano series in the Asia-Pacific region within the year [1] - There is a commitment to advance the commercial deployment of Universkin by Alma in the U.S. market [1] - The company is on track to orderly progress the commercialization of Daxif in mainland China [1]

Core Viewpoint - Foryou Medical Technology (01696) reported strong growth in new orders for Q3 2025, driven by performance in China, South Korea, and Thailand markets [1] Group 1: Financial Performance - The company achieved double-digit year-on-year growth in unaudited revenue for the quarter [1] Group 2: Product Development and Market Expansion - The flagship multi-functional device, Alma Harmony, experienced steady growth during the quarter [1] - The company plans to enhance the penetration of the Soprano series in the Asia-Pacific region within the year [1] - There is a commitment to advance the commercial deployment of Universkin by Alma in the U.S. market [1] - The company is on track to orderly progress the commercialization of Daxif in mainland China [1]

Core Viewpoint - Furuya Medical Technology (01696.HK) reported strong growth in new orders for Q3 2025, driven by performance in China, South Korea, and Thailand markets [1] Group 1: Financial Performance - The company achieved a double-digit year-on-year growth in unaudited revenue for the quarter [1] Group 2: Product Development and Market Expansion - The flagship multi-functional device, Alma Harmony, experienced steady growth during the quarter [1] - The company plans to enhance the penetration of the Soprano series in the Asia-Pacific region within the year [1] - There is a commitment to advance the commercial deployment of Universkin by Alma in the U.S. market [1] - The company is on track to orderly progress the commercialization of Daxif in mainland China [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 自願公告 業務更新 本公告由復銳醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 發佈，以通知本公司股東及潛在投資者有關本集團的最新業務狀況。 本公司欣然宣布，本集團於二零二五年第三季度的新訂單保持強勁增長勢頭，主 要得益於中國、韓國及泰國市場的表現。旗下多功能旗艦設備Alma Harmony於 本季度實現穩健增長。因此，本集團本季度未經審核收益實現同比雙位數增長。 憑藉持續的市場開拓和需求挖掘，本集團將於年內進一步推動Soprano系列在亞 太地區的滲透，全力推進Universkin by Alma在美國市場的商業部署。同時，按計 劃有序推進達希斐在中國大陸的商業化進程。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 本公告乃根據本公司董事會初步審閱本集團的未經審核營運數據初稿及董事會現 ...

Core Viewpoint - The announcement highlights a commercial distribution cooperation agreement between Furuya Medical Technology and Fosun Wanbang, focusing on the marketing and distribution of DaxibotulinumtoxinA-lanm, a product aimed at improving moderate to severe frown lines in adults [1] Group 1: Agreement Details - Furuya (Tianjin) will handle commercialization, marketing, medical education, and business planning services for the product, while Fosun Wanbang (Jiangsu) will manage import, procurement, customs clearance, warehousing, transportation, and general distribution [1] - The product, known as DAXXIFY, is a re-authorized product by Fosun for temporary improvement of frown lines caused by muscle activity [1] Group 2: Business Implications - The agreement aligns with the company's business model, allowing Furuya (Tianjin) to provide services as part of its routine operations [1] - The company has obtained rights for the product's use, import, sales, and other commercialization activities (excluding manufacturing), positioning it advantageously in the market [1] - The anticipated transactions from this agreement are expected to generate additional revenue, thereby strengthening the company's market position [1]

Investment Rating - The report maintains a "Buy" rating for the company [3][9][17] Core Views - The company's performance is temporarily under pressure due to external factors, particularly in North America, but there is optimism for recovery as the innovation pipeline progresses [3][16] - Revenue for H1 2025 was reported at $165 million, a slight decrease of 1.93% year-on-year, with adjusted net profit down 28.13% to $11.97 million [12][13] - The company is expected to see revenue growth from $395 million in 2025 to $530 million by 2027, with corresponding net profits increasing from $31.5 million to $57.39 million [3][11][17] Summary by Sections Financial Performance - H1 2025 revenue breakdown: - Asia-Pacific: $66 million (+17.64%), contributing 39.78% of total revenue - North America: $57 million (-15.56%), contributing 34.20% - Europe: $24 million (-0.84%), contributing 14.40% - Middle East & Africa: $14 million (-9.72%), contributing 8.41% - Latin America: $5 million (-15.83%), contributing 3.21% [2][13] - Medical aesthetics revenue was $138 million (-7.79%), while injection filling revenue surged to $14 million (+218.15%) [2][13] Cost and Profitability - The company's gross margin for H1 2025 was 60.04%, down 2.38 percentage points, with adjusted net profit margin at 7.23% [15] - Management expenses increased, leading to a slight rise in expense ratios, with total expenses at $11.97 million [14][15] Future Outlook - The energy source equipment business is expected to stabilize and grow as external conditions improve, with new product launches planned for H2 2025 [16][17] - The long-acting botulinum toxin product is anticipated to launch by the end of 2025, which could significantly enhance market recognition and sales [3][17]

Group 1: Market Trends - The traditional couple economy is cooling down, with a notable shift towards male consumers focusing on self-investment and personal interests [1][3][14] - Data shows that 30% of men plan to not give gifts during the 2024 "520" period, indicating a significant change in spending behavior [1] - The sales of the domestic game "Black Myth: Wukong" reached 9 billion yuan, primarily driven by male players, reflecting the rise of "self-consumption" among men [1] Group 2: Changing Consumer Behavior - The willingness to engage in romantic relationships among young people is declining, with both genders scoring around 5 out of 10 on their desire for romance [2][3] - The sales of DR diamond rings, once a symbol of true love, have seen a significant decline, with a 36.19% drop in revenue year-on-year [2] - The cinema attendance for romantic films is decreasing, replaced by a demand for family and solo viewing experiences [3] Group 3: Male Consumption Dynamics - Male consumers are increasingly spending on personal grooming and beauty products, with sales in categories like skincare and cosmetics for men reaching 1.86 billion yuan, a 65% increase year-on-year [5] - The male medical beauty market is also growing, with 45% of surveyed men planning to increase their spending on medical aesthetics in 2024 [7] - The average spending of male consumers online has surpassed that of females, reaching 10,025 yuan, with the male consumption market expected to exceed 6 trillion yuan by 2025, growing at a compound annual growth rate of 9.8% [4] Group 4: Marketing and Brand Strategy - Brands need to adapt to the shift from relationship-based consumption to individual needs, focusing on "solitary consumption" [9][10] - Marketing strategies are evolving from emphasizing product functionality to highlighting emotional value and identity recognition [12][13] - The rise of interest-based consumption is evident, with products becoming symbols of social identity, such as the "middle-class three-piece set" [8][12] Group 5: Future Outlook - The transformation in male consumer behavior is indicative of a broader market restructuring, where consumption is increasingly tied to personal meaning rather than mere transactions [14] - The emergence of new markets driven by single economy, technological empowerment, and evolving values is expected to create significant opportunities for brands [14]

Core Viewpoint - The article discusses the rising concerns and incidents related to the use of botulinum toxin (commonly known as Botox) in cosmetic procedures, highlighting the risks associated with unregulated products and practices in the medical beauty industry. Group 1: Incidents and Risks - Recent incidents involving celebrities, such as actress Qi Wei and actor Du Chun's wife, illustrate the potential dangers of excessive botulinum toxin injections and allergic reactions [1][2] - There has been a noticeable increase in discussions about botulinum toxin poisoning on the internet, with legal consultations regarding such cases rising significantly [4] - Many cases of poisoning stem from excessive dosages or counterfeit products, with reports of severe reactions including dizziness, weakness, and swallowing difficulties [4][10] Group 2: Market Dynamics - The botulinum toxin market in China is experiencing rapid growth, with projections indicating an increase from 3.9 billion yuan in 2020 to 11.4 billion yuan by 2025 [22] - The market has evolved from a dual-competitor landscape to a more diversified one, with multiple companies entering the space, including Huons, Hugel, and others [22][23] - Despite strict regulatory policies, the prevalence of counterfeit products remains high, posing significant safety risks to consumers [25][10] Group 3: Consumer Awareness and Safety - Consumers are often misled by unqualified practitioners and may not be aware of the products being used or their potential side effects [28][29] - It is crucial for consumers to verify the qualifications of medical institutions and practitioners, as well as the legitimacy of the products being used [28] - Recommendations for safe practices include ensuring the use of licensed medical facilities, qualified physicians, and legitimate products to mitigate risks associated with botulinum toxin injections [28][30]